244 related articles for article (PubMed ID: 30034229)
41. Post-Progression Survival after EGFR-TKI for Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutations.
Kogure Y; Saka H; Oki M; Saito TI; Ahmed SN; Kitagawa C; Imaizumi K
PLoS One; 2015; 10(8):e0135393. PubMed ID: 26262682
[TBL] [Abstract][Full Text] [Related]
42. Is there a specific phenotype associated with the different subtypes of KRAS mutations in patients with advanced non-small-cell lung cancers?
Dumenil C; Vieira T; Rouleau E; Antoine M; Duruisseaux M; Poulot V; Lacave R; Cadranel J; Massiani MA; Wislez M
Lung Cancer; 2015 Dec; 90(3):561-7. PubMed ID: 26520186
[TBL] [Abstract][Full Text] [Related]
43. Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.
Lim SH; Lee JY; Sun JM; Ahn JS; Park K; Ahn MJ
J Thorac Oncol; 2014 Apr; 9(4):506-11. PubMed ID: 24736073
[TBL] [Abstract][Full Text] [Related]
44. Final overall survival in JO22903, a phase II, open-label study of first-line erlotinib for Japanese patients with EGFR mutation-positive non-small-cell lung cancer.
Yamamoto N; Goto K; Nishio M; Chikamori K; Hida T; Maemondo M; Katakami N; Kozuki T; Yoshioka H; Seto T; Tajima K; Tamura T
Int J Clin Oncol; 2017 Feb; 22(1):70-78. PubMed ID: 27659294
[TBL] [Abstract][Full Text] [Related]
45. COPD may increase the incidence of refractory supraventricular arrhythmias following pulmonary resection for non-small cell lung cancer.
Sekine Y; Kesler KA; Behnia M; Brooks-Brunn J; Sekine E; Brown JW
Chest; 2001 Dec; 120(6):1783-90. PubMed ID: 11742902
[TBL] [Abstract][Full Text] [Related]
46. Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations.
Yeo CD; Park KH; Park CK; Lee SH; Kim SJ; Yoon HK; Lee YS; Lee EJ; Lee KY; Kim TJ
Lung Cancer; 2015 Mar; 87(3):311-7. PubMed ID: 25617986
[TBL] [Abstract][Full Text] [Related]
47. Chronic obstructive pulmonary disease and comorbidities' influence on mortality in non-small cell lung cancer patients.
Media AS; Persson M; Tajhizi N; Weinreich UM
Acta Oncol; 2019 Aug; 58(8):1102-1106. PubMed ID: 31092081
[No Abstract] [Full Text] [Related]
48. Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small-cell lung cancer.
Mitsudomi T; Oyama T; Kusano T; Osaki T; Nakanishi R; Shirakusa T
J Natl Cancer Inst; 1993 Dec; 85(24):2018-23. PubMed ID: 8246288
[TBL] [Abstract][Full Text] [Related]
49. p53 gene mutations are associated with shortened survival in patients with advanced non-small cell lung cancer: an analysis of medically managed patients.
Murakami I; Hiyama K; Ishioka S; Yamakido M; Kasagi F; Yokosaki Y
Clin Cancer Res; 2000 Feb; 6(2):526-30. PubMed ID: 10690534
[TBL] [Abstract][Full Text] [Related]
50. The impact of EGFR mutation status on outcomes in patients with resected stage I non-small cell lung cancers.
Izar B; Sequist L; Lee M; Muzikansky A; Heist R; Iafrate J; Dias-Santagata D; Mathisen D; Lanuti M
Ann Thorac Surg; 2013 Sep; 96(3):962-8. PubMed ID: 23932319
[TBL] [Abstract][Full Text] [Related]
51. Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer: a comprehensive analysis of 26,957 patients with NSCLC.
Kawaguchi T; Takada M; Kubo A; Matsumura A; Fukai S; Tamura A; Saito R; Maruyama Y; Kawahara M; Ignatius Ou SH
J Thorac Oncol; 2010 May; 5(5):620-30. PubMed ID: 20354456
[TBL] [Abstract][Full Text] [Related]
52. PGAM5 expression and macrophage signatures in non-small cell lung cancer associated with chronic obstructive pulmonary disease (COPD).
Ng Kee Kwong F; Nicholson AG; Pavlidis S; Adcock IM; Chung KF
BMC Cancer; 2018 Dec; 18(1):1238. PubMed ID: 30526542
[TBL] [Abstract][Full Text] [Related]
53. Prospective cohort study of clinical characteristics and management patterns for patients with non-small-cell lung cancer in the Russian Federation: EPICLIN-Lung.
Tjulandin S; Imyanitov E; Moiseyenko V; Ponomarenko D; Gurina L; Koroleva I; Karaseva V
Curr Med Res Opin; 2015 Jun; 31(6):1117-27. PubMed ID: 25867537
[TBL] [Abstract][Full Text] [Related]
54. Changes in the natural history of nonsmall cell lung cancer (NSCLC)--comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990.
Wakelee HA; Bernardo P; Johnson DH; Schiller JH
Cancer; 2006 May; 106(10):2208-17. PubMed ID: 16604529
[TBL] [Abstract][Full Text] [Related]
55. A phase II study of docetaxel and carboplatin in Thai patients with advanced non-small-cell lung cancer.
Thongprasert S; Soorraritchingchai S; Chewaskulyong B; Charoentum C; Munprakan S
J Med Assoc Thai; 2006 Feb; 89(2):152-9. PubMed ID: 16579000
[TBL] [Abstract][Full Text] [Related]
56. Survival associated with chronic obstructive pulmonary disease among SEER-Medicare beneficiaries with non-small-cell lung cancer.
Shah S; Blanchette CM; Coyle JC; Kowalkowski M; Arthur ST; Howden R
Int J Chron Obstruct Pulmon Dis; 2019; 14():893-903. PubMed ID: 31118599
[No Abstract] [Full Text] [Related]
57. The presence of mutations in epidermal growth factor receptor gene is not a prognostic factor for long-term outcome after surgical resection of non-small-cell lung cancer.
Kim YT; Seong YW; Jung YJ; Jeon YK; Park IK; Kang CH; Kim JH
J Thorac Oncol; 2013 Feb; 8(2):171-8. PubMed ID: 23287850
[TBL] [Abstract][Full Text] [Related]
58. Prognostic factors in older patients with advanced non-small cell lung cancer in China.
Su Q; Sun YP; Liu YH; Li Z; Yang HY; Sun ZG; Cao BW; Jia JH
Tumori; 2014; 100(1):69-74. PubMed ID: 24675494
[TBL] [Abstract][Full Text] [Related]
59. Neoadjuvant chemotherapy with docetaxel-cisplatin in patients with stage III N2 non-small-cell lung cancer.
Liao WY; Chen JH; Wu M; Shih JY; Chen KY; Ho CC; Yang JC; Yu CJ
Clin Lung Cancer; 2013 Jul; 14(4):418-24. PubMed ID: 23291258
[TBL] [Abstract][Full Text] [Related]
60. EGFR mutations and clinical outcomes of chemotherapy for advanced non-small cell lung cancer: a meta-analysis.
Zhang Q; Dai HH; Dong HY; Sun CT; Yang Z; Han JQ
Lung Cancer; 2014 Sep; 85(3):339-45. PubMed ID: 25043903
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
